IGF2BP1 and gastric cancer: Furthermore, it is possible to extend the FTO‐FOS‐IGF2BP1/2 axis as biomarkers to all patients with GC, regardless of their EBV infection status, and detecting the expression of this biomarker panel could predict the prognosis of GC patients.